Modified Fatigue Impact Scale

Abstract

The Modified Fatigue Impact Scale (MFIS) is a standardized, multidimensional patient-reported outcome measure (PROM) developed to assess the perceived effects of fatigue on everyday functioning in individuals with chronic neurodegenerative and systemic conditions, most notably multiple sclerosis (MS). Derived from the original 40-item Fatigue Impact Scale (FIS; Fisk et al., 1994) by the Multiple Sclerosis Council for Clinical Practice Guidelines in 1998, the MFIS condenses the assessment into a pragmatic 21-item instrument. The scale queries functional limitations experienced over a 4-week recall period across three core domains: physical functioning (9 items), cognitive functioning (10 items), and psychosocial functioning (2 items). Each item is rated on a 5-point Likert-type scale ranging from 0 (Never) to 4 (Almost always), producing a total score from 0 to 84, where higher scores signify greater disruption of daily living attributable to fatigue.

Extensive psychometric evaluations have demonstrated that the MFIS possesses high internal consistency, with Cronbach’s alpha values routinely exceeding .90 for the total score and ranging between .81 and .92 across the subscales. Test-retest reliability across clinical trials and observational cohorts is robust (intraclass correlation coefficients ranging from .76 to .91). Construct validity is confirmed through convergent associations with generic and disease-specific fatigue instruments, such as the Fatigue Severity Scale (FSS), while discriminant validity is maintained against overlapping constructs including clinical depression and generalized physical disability measured via the Expanded Disability Status Scale (EDSS). Although factor analytic investigations debate whether the instrument functions as a strict three-dimensional model or a strong general factor with sub-dimensions, the MFIS remains an international gold standard in neuro-rehabilitation and clinical trials.

Keywords

Modified Fatigue Impact Scale, MFIS, multiple sclerosis, fatigue impact, cognitive fatigue, physical fatigue, psychosocial functioning, psychometrics, patient-reported outcome measure, neuro-rehabilitation, Fatigue Impact Scale, disability evaluation.

Authors

The Modified Fatigue Impact Scale was adapted from the original Fatigue Impact Scale (FIS) authored by John D. Fisk, Ph.D., Paul G. Ritvo, Ph.D., Luanne Ross, R.N., David A. Haase, M.D., T. Jock Murray, M.D., and Reg L. Licinio, Ph.D. (1994) at Dalhousie University and the Nova Scotia Persons with MS Research Group in Halifax, Nova Scotia, Canada.

The shortened 21-item modification was formally codified and disseminated in 1998 by the Multiple Sclerosis Council for Clinical Practice Guidelines, an expert clinical consensus panel convened by the Paralyzed Veterans of America (PVA) and supported by the National Multiple Sclerosis Society (NMSS) in the United States. Prominent translational adaptations include the validated Dutch edition standardized by Daphne Kos, Ph.D., Eric Kerckhofs, Ph.D., and colleagues (2003) within neuro-rehabilitation centers across Belgium and the Netherlands.

Purpose

Fatigue is recognized as one of the most pervasive, disabling, and poorly understood symptoms across chronic neurological pathologies. In multiple sclerosis, between 75% and 90% of individuals report clinically meaningful fatigue, with over half citing it as one of their most debilitating symptoms leading to vocational withdrawal, social isolation, and compromised health-related quality of life. Despite its prevalence, measuring fatigue poses significant epistemological and psychometric hurdles because of its subjective phenomenology and multi-faceted etiology.

The primary clinical and research objective of the MFIS is to evaluate not merely the severity or subjective intensity of fatigue (i.e., how exhausted an individual feels), but specifically the impact or functional consequence of fatigue on discrete domains of everyday life. Differentiating impact from intensity is essential: an individual may experience profound subjective lassitude yet maintain daily compensatory routines, whereas another individual with moderate fatigue may experience complete functional collapse in workplace concentration or family participation. The MFIS addresses this clinical imperative by operationalizing functional decrements over a stable retrospective window of four weeks.

In clinical trials and pharmacological interventions, the MFIS serves as a responsive primary or secondary endpoint to track changes following neuroprotective, immunomodulatory, or symptomatic pharmacotherapies (such as amantadine, modafinil, or fampridine). In neuro-rehabilitation and psychological settings, the instrument aids clinicians in tailoring multi-component interventions, such as energy conservation management (ECM), physical exercise programs, and cognitive behavioral therapy (CBT). By delineating whether an individual’s primary deficit lies within physical breakdown, executive cognitive slowing, or social withdrawal, clinicians can implement targeted interventions rather than generic fatigue protocols.

Psychological Construct

The core construct measured by the MFIS is the perceived functional disruption caused by fatigue across biological, psychological, and social strata. Rather than framing fatigue as a unitary biological symptom, the scale approaches it as a multidimensional construct comprising three distinct yet interrelated domains:

1. Physical Impact Domain

The physical subscale encompasses 9 items designed to capture the structural, motoric, and homeostatic restrictions imposed by exhaustion. In neurodegenerative conditions such as MS, amyotrophic lateral sclerosis (ALS), or post-stroke syndrome, physical fatigue reflects both central motor drive failure and peripheral neuromusculoskeletal fatigue. This domain assesses:

• Motor coordination and stability: Clumsiness, uncoordinated movements, and muscular weakness during execution of motor programs (e.g., Item 4, Item 13).
• Pacing and task persistence: The necessity to pace movement, difficulty maintaining physical effort over sustained periods, and the premature cessation of motor activities (e.g., Item 6, Item 10).
• Somatic discomfort and restriction: Generalized bodily discomfort associated with exertion and the enforced reduction of activities of daily living (e.g., Item 14, Item 20).

2. Cognitive Impact Domain

The cognitive subscale consists of 10 items evaluating the subjective perception of mental exhaustion and secondary executive dysfunction. In neurological conditions, cognitive fatigue often diverges from objective neuropsychological performance, reflecting an excessive compensatory neural resource allocation required to maintain task processing speed. This subscale measures:

• Sustained and selective attention: Reduced vigilance, inability to maintain attention during complex tasks, and distractibility (e.g., Item 1, Item 2, Item 19).
• Information processing speed and clarity: Bradyphrenia (slowed cognitive processing), mental clouding, and difficulty organizing thoughts in domestic or professional environments (e.g., Item 3, Item 16, Item 18).
• Executive functioning and memory retrieval: Impairments in short-term recall, working memory operations, decision-making, and initiating tasks that demand active problem-solving (e.g., Item 5, Item 11, Item 12, Item 15).

3. Psychosocial Impact Domain

The psychosocial subscale is an abbreviated 2-item index reflecting the broader social ecology and motivational drive of the individual. Neurological fatigue frequently diminishes the hedonic and motivational salience required for interpersonal and leisure engagement. This subscale specifically indexes:

• Social motivation and isolation: Decreased motivation to engage in social events, family interactions, and relational leisure (Item 8).
• Occupational and participatory competence: Decrements in completing broader vocational or communally situated tasks that demand physical or interactive vigor (Item 9).

Theoretical Framework

The conceptual framework underpinning the MFIS draws directly from the Biopsychosocial Model of Illness (Engel, 1977) and the World Health Organization’s International Classification of Functioning, Disability and Health (ICF) framework. Within the ICF paradigm, health states are categorized into body functions/structures, activities (execution of tasks), and participation (involvement in life situations). While clinical biological markers (such as MRI lesion burden or inflammatory cytokines) reflect physiological impairment, the MFIS operationalizes the downstream consequences: activity limitations and participation restrictions.

Early work by Fisk et al. (1994) addressed a theoretical gap in fatigue literature: prevailing scales at the time, such as the Fatigue Severity Scale (Krupp et al., 1989), were predominantly unidimensional and weighted heavily toward motoric and physical symptoms. This led to ceiling effects and failed to capture the profound “brain fog” and executive slowing experienced by patients with demyelinating disease. In contrast, cognitive psychology paradigms argue that cognitive fatigue reflects depletion of finite central executive resources (Baddeley’s working memory model) and dysregulation within the cortico-striatal-thalamic circuits responsible for effort-reward computation (Chaudhuri & Behan, 2004).

When the Multiple Sclerosis Council for Clinical Practice Guidelines met in 1998 to establish evidence-based standards for fatigue management, they recognized that the full 40-item FIS placed an excessive burden on fatigued patients. Drawing on classical test theory, they conducted item reduction to create a pragmatic scale that preserved the conceptual balance across physical, cognitive, and psychosocial domains. The resulting 21-item framework assumes that fatigue is an interactive multidimensional experience where central neural pathobiology, cognitive resource allocation, and psychosocial context reciprocally amplify disability.

Validity

The construct, convergent, and discriminant validity of the MFIS have been documented across numerous studies internationally:

Construct and Structural Validity

Construct validity is substantiated by the scale’s capacity to differentiate healthy populations from clinical cohorts (e.g., MS, ALS, Parkinson’s disease, chronic fatigue syndrome). Individuals with definitive MS diagnoses consistently score significantly higher across all three subscales compared to age- and sex-matched healthy controls ($p < .001$). Furthermore, the scale displays graded differentiation across differing clinical courses of MS, with patients diagnosed with secondary progressive MS (SPMS) typically demonstrating higher total and physical impact scores than those with relapsing-remitting MS (RRMS).

Convergent Validity

The MFIS exhibits moderate-to-high correlations with other validated fatigue measures, supporting its convergent validity:

• Fatigue Severity Scale (FSS): Total MFIS scores correlate strongly with the FSS ($r = .65$ to $.78, p < .001$). Notably, the physical subscale of the MFIS shares the highest correlation with the FSS, reflecting the motor emphasis of Krupp’s original scale.
• Visual Analogue Scale for Fatigue (VAS-F): Correlations between the MFIS total score and instantaneous or daily VAS fatigue ratings range from $r = .52$ to $.68$.
• Short Form-36 (SF-36): The MFIS correlates negatively with the Vitality ($r = -.60$ to $-.74$) and Physical Functioning subscales ($r = -.50$ to $-.65$), confirming that elevated fatigue impact aligns with diminished health-related quality of life.

Discriminant and Divergent Validity

A perennial psychometric challenge in fatigue assessment is disentangling fatigue from depression. Multiple studies evaluating the MFIS alongside the Beck Depression Inventory (BDI-II) and the Hospital Anxiety and Depression Scale (HADS) reveal moderate intercorrelations ($r = .40$ to $.55$). While this indicates shared affective variance, factor analytic and regression models demonstrate that the MFIS physical and cognitive domains account for unique variance in functional disability after partialling out depressive affect. Furthermore, the correlation between the MFIS and neurological impairment as measured by the EDSS is modest ($r = .25$ to $.40$), demonstrating that fatigue impact is largely independent of focal neurological physical disability.

Reliability

The MFIS demonstrates strong reliability metrics across varying administrative contexts, languages, and clinical subgroups:

Internal Consistency

Internal consistency estimates via Cronbach’s alpha ($lpha$) consistently fall within the excellent range for the aggregate instrument and good-to-excellent ranges for its constituent subscales:

• Total MFIS Score (21 items): $lpha = .92$ to $.96$ across American, Dutch, Italian, Spanish, and Persian validation cohorts.
• Physical Subscale (9 items): $lpha = .88$ to $.92$.
• Cognitive Subscale (10 items): $lpha = .85$ to $.91$.
• Psychosocial Subscale (2 items): $lpha = .65$ to $.81$. Given that this subscale contains only two items, a slightly lower alpha is psychometrically expected due to the structural dependence of Cronbach’s alpha on scale length; Spearman-Brown split-half reliability remains high ($r > .75$).

Test-Retest Reliability

Stability across time in clinically stable patients has been confirmed over test-retest intervals ranging from 7 days to 4 weeks:

• Intraclass Correlation Coefficients (ICC): Total score ICC values consistently range from $.76$ to $.91$, demonstrating high temporal stability in the absence of therapeutic intervention or acute disease exacerbations.
• Subscale Stability: ICC values for the physical domain typically exceed $.85$, while the cognitive domain yields ICCs between $.74$ and $.86$.
• Standard Error of Measurement (SEM) & Minimal Clinically Important Difference (MCID): Contemporary psychometric studies estimate the SEM of the total MFIS to be approximately $3.5$ to $4.2$ points. The MCID has been empirically determined to be a reduction or increase of approximately $4$ to $10$ points (or a $ge 20%$ change from baseline), providing a threshold for evaluating clinical trials and individual patient trajectories.

Factor Analysis

The structural dimensionality of the MFIS has been the subject of extensive psychometric investigation, centering on the structural validity of the original 3-factor model compared to alternative unidimensional or bi-factor solutions:

Exploratory Factor Analysis (EFA)

In early EFA studies utilizing principal axis factoring and varimax/promax rotations, the three-factor structure originally posited by Fisk and the MS Council accounted for approximately $55%$ to $65%$ of the total variance. Physical items (Items 4, 6, 7, 10, 13, 14, 17, 20) loaded substantially onto Factor 1 (factor loadings ranging from $.58$ to $.84$). Cognitive items (Items 1, 2, 3, 5, 11, 12, 15, 16, 18) loaded heavily onto Factor 2 (loadings from $.52$ to $.82$). Psychosocial items (Items 8 and 9) alongside physical item 7 loaded onto a distinct relational/participatory factor, though Item 9 frequently demonstrated dual-loading across both physical and psychosocial constructs.

Confirmatory Factor Analysis (CFA)

Confirmatory factor analytic investigations have yielded nuanced findings regarding model fit:

• Three-Factor Correlated Model: The traditional three-factor model demonstrates moderate-to-good fit indices across cohorts (e.g., Comparative Fit Index [CFI] $= .90 – .93$; Tucker-Lewis Index [TLI] $= .89 – .92$; Root Mean Square Error of Approximation [RMSEA] $= .06 – .08$). However, exceptionally high correlations between the physical and cognitive factors ($r > .70$), and between the psychosocial factor and the others ($r > .75$), suggest substantial latent overlap.
• Bi-factor and Unidimensional Models: Several modern psychometric analyses using item response theory (IRT) and Rasch analysis (e.g., Mills et al., 2010; Rietberg et al., 2010) suggest that the MFIS is predominantly driven by a single strong, overarching general factor representing “Generalized Fatigue Impact.” These analyses argue that while the subscales provide useful clinical descriptors, the total score carries the highest psychometric reliability and structural fidelity for research purposes.

Instrument / Measurement Tool

• Instrument Name: Modified Fatigue Impact Scale (MFIS).
• Derived From: Fatigue Impact Scale (FIS; Fisk et al., 1994).
• Type of Assessment: Self-administered patient-reported outcome measure (PROM) / Rating questionnaire.
• Target Population: Adults and older adults diagnosed with multiple sclerosis (relapsing-remitting, secondary progressive, primary progressive), as well as clinical cohorts with amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI), post-polio syndrome, stroke, or chronic fatigue syndrome.
• Recall Period: Past 4 weeks (“Because of my fatigue during the past 4 weeks…”).
• Administration Time: Approximately 5 to 10 minutes.
• Total Item Count: 21 items.
• Subscale Composition:
  • Physical Subscale (9 items): Items 4, 6, 7, 10, 13, 14, 17, 19, 20 (Range: 0–36).
  • Cognitive Subscale (10 items): Items 1, 2, 3, 5, 11, 12, 15, 16, 18, 21 (Range: 0–40).
  • Psychosocial Subscale (2 items): Items 8, 9 (Range: 0–8).
• Response Format: 5-point Likert rating scale:
  • 0 = Never
  • 1 = Rarely
  • 2 = Sometimes
  • 3 = Often
  • 4 = Almost always
• Scoring and Interpretation:
  • Total Score: Calculated by summing all 21 items (Theoretical Range: 0 to 84). Higher scores indicate greater impact of fatigue on daily life.
  • Subscale Scores: Summed independently within their respective designated item clusters.
  • Reverse Scoring: None. All items are positively phrased relative to functional limitation.
  • Missing Data Rules: If fewer than 3 items are missing across the scale, mean imputation based on the valid subscale items is commonly applied; if 3 or more items are missing, the questionnaire is generally deemed invalid.
  • Clinical Cut-Off: A validated total score cut-off of $ge 38$ is widely recognized in multiple sclerosis literature to categorize individuals as “fatigued” or experiencing clinically significant fatigue impact (Flachenecker et al., 2002).

Permissions & Fee and Test Year

The Modified Fatigue Impact Scale was formulated and officially published in 1998 by the Multiple Sclerosis Council for Clinical Practice Guidelines under the auspices of the Paralyzed Veterans of America (PVA). The instrument was placed into the public domain to facilitate unencumbered academic research, clinical neuro-rehabilitation assessment, and health outcomes tracking.

There are no licensing fees, royalties, or formal administrative costs associated with using the standard 21-item MFIS for individual clinical use or non-commercial academic research. The instrument is accessible via the National Multiple Sclerosis Society and neurological outcomes repositories. Users are expected to maintain the exact wording, response formatting, and 4-week recall window of the items to preserve psychometric comparability, and appropriate attribution to the Multiple Sclerosis Council (1998) and Fisk et al. (1994) must be included in scholarly publications.

References

• Chaudhuri, A., & Behan, P. O. (2004). Fatigue in neurological disorders. The Lancet, 363(9413), 978–988. https://doi.org/10.1016/S0140-6736(04)15794-2
• Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460
• Fisk, J. D., Ritvo, P. G., Ross, L., Haase, D. A., Murray, T. J., & Licinio, R. L. (1994). Measuring the functional impact of fatigue: Initial validation of the Fatigue Impact Scale. Clinical Infectious Diseases, 18(Suppl 1), S79–S83. https://doi.org/10.1093/clinids/18.suppl_1.s79
• Flachenecker, P., Kümpfel, T., Kallmann, B., Gottschalk, M., Grauer, O., Rieckmann, P., Trenkwalder, C., & Toyka, K. V. (2002). Fatigue in multiple sclerosis: A comparison of different rating scales and correlation to clinical parameters. Multiple Sclerosis Journal, 8(6), 523–526. https://doi.org/10.1191/1352458502ms839oa
• Kos, D., Kerckhofs, E., Carrea, I., Verza, R., Ramos, M., & Jansa, J. (2003). Evaluation of the Modified Fatigue Impact Scale in four different European countries. Multiple Sclerosis Journal, 9(Suppl 1), S86.
• Kos, D., Nagels, G., D’Hooghe, M. B., Duportail, M., & Kerckhofs, E. (2006). A comparison of the Modified Fatigue Impact Scale (MFIS) and the Fatigue Severity Scale (FSS) in multiple sclerosis. Multiple Sclerosis Journal, 12(4), 518–521. https://doi.org/10.1191/1352458506ms1321oa
• Krupp, L. B., LaRocca, N. G., Muir-Nash, J., & Steinberg, A. D. (1989). The Fatigue Severity Scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology, 46(10), 1121–1123. https://doi.org/10.1001/archneur.1989.00520460115022
• Mills, R. J., Young, C. A., Pallant, J. F., & Tennant, A. (2010). Rasch analysis of the Modified Fatigue Impact Scale in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 81(9), 1049–1051. https://doi.org/10.1136/jnnp.2009.183129
• Multiple Sclerosis Council for Clinical Practice Guidelines. (1998). Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Paralyzed Veterans of America. Washington, DC.
• Rietberg, M. B., van Wegen, E. E., & Kwakkel, G. (2010). Measuring fatigue in patients with multiple sclerosis: Reproducibility, responsiveness and concurrent validity of three Dutch fatigue questionnaires. Disability and Rehabilitation, 32(22), 1870–1876. https://doi.org/10.3109/09638281003734441

13. Items of the Scale (Questionnaire)